Sign in

Trial result ·

BCMA-directed CAR T-cell therapy induces durable drug-free remission in refractory primary immune thrombocytopenia.

Written based on 1 research study on PubMed, searched on 13 Nov 2026.

What was studied

This trial tested a new cell treatment for immune thrombocytopenia, called ITP. It included 4 people whose ITP had not got better with other care. The treatment is called BCMA CAR T-cell therapy. It uses changed T cells that aim at a target called BCMA. This was an early-stage trial of safety and how well it worked.

What they found

The abstract says the safety of the treatment was manageable. Platelet levels came back quickly, and the rise held steady. Full remission without ITP drugs was reported. This drug-free remission lasted up to 15 months. The abstract does not say how many of the 4 people reached it. It gives no more detailed results.

What it means for patients

The authors report that the treatment can bring lasting remission without drugs. This was seen in people whose ITP was hard to treat. For now, these results come from only 4 people.

Why it is not certain yet

Only 4 people were treated in this trial. The abstract does not mention a comparison group. Remission was reported for up to 15 months only. The abstract does not say what happens after that. It gives no details on side effects. Early-stage trials are small and mainly check safety.

The registered trial

The paper names this trial from a public trial registry. Its page shows who the trial is for, its sites and its status.

Source

BCMA-directed CAR T-cell therapy induces durable drug-free remission in refractory primary immune thrombocytopenia.

PubMed · PMID 42498681

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Immune thrombocytopenia (ITP) publications